Dr. Reddy's: Preparing for Tomorrow's Needs Today

Dr. Reddy's Laboratories Inc (Bridgewater, NJ) began generic operations in the second half of 2001, marketing its products principally in North America (United States and Canada) and the European Union. Dr. Reddy's mission is to fulfill 2 core purposes: first, to provide patients with access to high-quality generic medicines at affordable prices; and second, to develop new treatments that satisfy unmet medical needs, which are improvements over currently existing therapies.

The company currently markets 25 products in more than 119 presentations under its label in the United States.

Dr. Reddy's North America generics group has demonstrated its desire to be the first choice for its customers:

• The company is vertically integrated in more than 90% of its products, allowing it to compete in a marketplace that increasingly has pricing pressures and multiple competitors.
• Dr. Reddy's has launched an OTC division and also is positioned to support prescription-to-OTC switches. This group brings vertical integration and development expertise to the US OTC private label market.
• The company is very aggressive in its generic pipeline, having the second largest number of Paragraph IV products filed with the FDA. This creates significant value potential for customers and complements a portfolio of marketed products and a large pipeline.
• Dr. Reddy's has proven expertise in sales, marketing, regulatory, sales operations, and supply chain, with an average tenure of team members in North America being more than 18 years. The company has rich and tested experience in regulatory matters and logistics management.

The need to bring more people into the health care system increases every day. The pharmaceutical industry is challenged to find costeffective solutions. By providing alternatives to highly priced innovator brands through generics, Dr. Reddy's strives to make medicines more accessible and affordable to people all over the world.

Products

Marketed by: Dr. Reddy's Laboratories Inc (Bridgewater, NJ)

Ciprofloxacin Tablets, USP

Indication:

Ciprofloxacin Tablets, USP, are antibiotics indicated for the treatment or prevention of certain infections caused by bacteria. The product is also used to treat or prevent anthrax in people who may have been exposed to anthrax germs in the air. The product is the generic equivalent of Bayer HealthCare's Cipro and comes in 250-, 500-, and 750-mg tablets.

Ondansetron HCl Tablets

Indication:

Ondansetron HCl Tablets are indicated for the prevention of nausea and vomiting associated with highly or moderatelyemetogenic chemotherapy; radiotherapy in patients receiving either total body irradiation, single high-dose fraction to theabdomen, or daily fractions to the abdomen; or postoperative nausea and/or vomiting. The product is the generic equivalent of GlaxoSmithKline's Zofran and comes in 4-, 8-, and 24-mg tablets.

Simvastatin Tablets, USP

Indication:

Simvastatin Tablets, USP, are indicated for the reduction of elevated total and low-density lipoprotein cholesterol levels, and to increase high-density lipoprotein cholesterol levels, in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia, or homozygous familial hypercholesterolemia (as an adjunct to other lipid-lowering treatments). The product comes in tablets of 10, 20, 40, and 80 mg.

For More Information: www.drreddys.com or 866-733-3952.